



358 South Main Street
Burlington, NC 27215
Telephone: (336) 584-5171

FOR IMMEDIATE RELEASE

Contact:

Paul Surdez (investors) - 336-436-5076

Investor@labcorp.com

Pattie Kushner (media) - 336-436-8263

Media@labcorp.com

Company Information: www.labcorp.com

LabCorp Completes Acquisition of Assets of Pathology, Inc.

BURLINGTON, N.C. – March 21, 2016 – Laboratory Corporation of America[®] Holdings (LabCorp[®]) (NYSE: LH) has completed the previously-announced acquisition of substantially all of the operating assets of Pathology, Inc. following the satisfaction of all closing conditions. The acquisition includes Pathology, Inc.'s patient service centers used to conduct its medical testing and services business.

“The added capabilities of Pathology, Inc. enhance our existing women’s health offerings and support LabCorp’s strategic vision to provide world class diagnostics that improve health and improve lives,” said David P. King, chairman and chief executive officer. “The environment for complementary acquisitions is favorable, and we expect to continue to expand our geographic footprint, test menu and unique capabilities in diagnostics, drug development and food safety through disciplined acquisitions that generate attractive financial returns.”

About LabCorp[®]

Laboratory Corporation of America[®] Holdings, an S&P 500 company, is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services through LabCorp Diagnostics, and end-to-end drug development support through Covance Drug Development. LabCorp is a pioneer in commercializing new diagnostic technologies and is improving people’s health by delivering the combination of world-class diagnostics, drug development and knowledge services. With net revenue in excess of \$8.5 billion in 2015 and more than 50,000 employees in approximately 60 countries, LabCorp offers innovative solutions to healthcare stakeholders. LabCorp clients include physicians, patients and consumers, biopharmaceutical companies, government agencies, managed care organizations, hospitals, and clinical labs. To learn more about Covance Drug Development, visit www.covance.com. To learn more about LabCorp and LabCorp Diagnostics, visit www.labcorp.com.

This press release contains forward-looking statements including with respect to estimated 2016 guidance and the impact of various factors on operating results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, adverse actions of governmental and other third-party payers and the results from the Company’s acquisition of Covance. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp’s operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2015, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC, as well as in the risk factors included in Covance’s filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2015, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

###